Stabilized insulin formulations

• US 6,852,694 B2
• Filed: 02/21/2002
• Issued: 02/08/2005
• Est. Priority Date: 02/21/2001
• Status: Active Grant

• Current Assignee: Medtronic Minimed Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Minimed Incorporated (Medtronic Plc)
• Inventors: Van Antwerp, William Peter, Gulati, Poonam S.
• Primary Examiner(s): Tate, Christopher R.
• Assistant Examiner(s): CHISM, BILLY D
• Application Number:
  US10/080,034
• Publication Number:
  US 20020132760A1
• Time in Patent Office: 1,083 Days
• Field of Search: 514/13, 514/3, 514/12, 514/4, 530/303, 530/304, 530/325, 530/333, 530/338
• US Class Current: 514/6.3
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/28 Insulins

Abstract

The present invention is directed to stabilized insulin composition comprising a mixture of insulin species such as insulin and an insulin analog. As disclosed herein, insulin compositions comprising a mixture of insulin and insulin analog species form heterodimeric complexes having a greater stability than the homodimeric complexes formed in compositions comprising single insulin species. Consequently, the present invention provides methods for stabilizing insulin molecules, methods for identifying stable heterodimeric insulin complexes and stabilized insulin compositions.

Claims

1. A method of making an insulin heterodimer composition, the method comprising:

(a) selecting a first insulin species comprising human insulin and a second insulin species comprising a human insulin polypeptide having an amino acid substitution at position 28 in the beta chain;

(b) adding the first insulin species and the second insulin species together in a aqueous solution comprising a pharmaceutically acceptable carrier;

(c) allowing the first insulin species and the second insulin species to associate in the solution so that the insulin heterodimer composition is made;

wherein the first insulin species and the second insulin species are selected so that the heterodimer formed by the first insulin species and the second insulin species is more stable than a homodimer formed by the second insulin species.

2. The method of claim 1, wherein the second insulin species is AspB28 insulin.

3. The method of claim 1, wherein the second insulin species is LISPRO insulin.

4. The method of claim 3, wherein the human insulin comprises from about 1% to about 50of the insulin of the composition and wherein the LISPRO insulin comprises from about 50% to about 99% of the insulin of the composition.

5. The method of claim 4, wherein the human insulin comprises from about 5% to about 20% of the insulin of the composition and wherein the LISPRO insulin comprises from about 95to about 80% of the insulin of the composition.

6. The method of claim 1, wherein the composition is a pharmaceutical composition.

7. A method of stabilizing an insulin composition comprising:

(a) selecting a first insulin species comprising human insulin and a second insulin species comprising;

a human insulin polypeptide having a P28D amino acid Substitution in the insulin beta chain;

or

a human insulin polypeptide having a P28K/K29P amino acid substitution in the insulin beta chain;

wherein the first insulin species and the second insulin species are selected such that a heterodimer formed by the first insulin species and the second insulin species is more stable than a homodimer formed by the second insulin species;

(b) adding the first insulin species and the second insulin species together in a aqueous solution comprising a pharmaceutically acceptable carrier;

(c) allowing the first insulin species and the second insulin species to associate in the solution so that a insulin heterodimer is formed by the first insulin species and the second insulin species;

so that the insulin composition is stabilized.

8. The method of claim 7, wherein the second insulin species is AspB28 insulin.

9. The method of claim 7, wherein the second insulin species is LISPRO insulin.

10. The method of claim 9, wherein the human insulin comprises from about 1% to about 50% of the insulin of the composition and wherein the LISPRO insulin comprises from about 50% to about 99% of the insulin of the composition.

11. The method of claim 10, wherein the human insulin comprises from about 5% to about 20% of the insulin of the composition and wherein the LISPRO insulin comprises from about 95% to about 80% of the insulin of the composition.

12. The method of claim 11, wherein the composition is a pharmaceutical composition.

13. A method of making an insulin heterodimer composition, the method comprising:

(a) adding human insulin and LISPRO insulin together in an aqueous solution comprising a pharmaceutically acceptable carrier;

(b)allowing the human insulin and LISPRO insulin to associate in the solution so that the insulin heterodimer composition is made;

wherein the human insulin and LISPRO insulin are selected so that a heterodimer formed by the human insulin and LISPRO insulin is more stable than a homodimer formed by the human insulin or a homodimer formed by the LISPRO insulin.

14. The method of making an insulin heterodimer composition, the method comprising:

(a) selecting a first insulin species comprising human insulin and a second insulin species comprising a variant of human insulin polypeptide having at least one amino acid substitution;

(b) adding the first insulin species and the second insulin species together in a aqueous solution comprising a pharmaceutically acceptable carrier;

(c) allowing the first insulin species and the second insulin species to associate in the solution so that the insulin heterodimer composition is made;

wherein the first insulin species and the second insulin species are selected so that the heterodimer formed by the first insulin species and the second insulin species is more stable than a homodimer formed by the second insulin species.